Icon plc (ICLR) Receives a Hold from Barclays

By Carrie Williams

Barclays analyst Jack Meehan maintained a Hold rating on Icon plc (ICLRResearch Report) yesterday and set a price target of $154. The company’s shares closed yesterday at $133.19.

According to TipRanks.com, Meehan is a 4-star analyst with an average return of 6.9% and a 62.1% success rate. Meehan covers the Healthcare sector, focusing on stocks such as Bio-Rad Laboratories, PRA Health Sciences, and IQVIA Holdings Inc.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Icon plc with a $157.25 average price target.

See today’s analyst top recommended stocks >>

Based on Icon plc’s latest earnings release for the quarter ending December 31, the company reported a quarterly net profit of $88.16 million. In comparison, last year the company had a net profit of $78.1 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

ICON plc is a contract research organization, which engages in the provision of outsourced development services to the pharmaceutical, biotechnology, and medical device industries. It operates through the following geographical segments: Ireland, Rest of Europe, United States, and Other.